Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Savara Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, ANNOUNCED TODAY THAT IT HAS RESUBMITTED THE MOLBREEVI BLA TO THE FDA, WITH FUJIFILM AS THE DRUG SUBSTANCE MANUFACTURER. THE MOLBREEVI BLA SUBMISSION IS SEEKING APPROVAL FOR THE TREATMENT OF AUTOIMMUNE PAP, A CHRONIC AND DEBILITATING RARE LUNG DISEASE CHARACTERIZED BY THE ABNORMAL BUILD-UP OF SURFACTANT IN THE ALVEOLI. THE COMPANY HAS REQUEST.

SAVARA RESUBMITS THE BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR MOLBREEVI* FOR THE POTENTIAL TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM WILL PRESENT AND HOST ONE ON ONE MEETINGS AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. DATE/TIME OF PRESENTATION: WEDNESDAY, JANUARY 14, 5:15PM PT/8:15PM ET PRESENTER: MATT PAULS, CHAIR AND CHIEF EXECUTIVE OFFICER, SAVARA LOCATION: WESTIN ST. FRANCIS, SAN FRANCISCO, ELIZABETHAN B.

SAVARA ANNOUNCES PARTICIPATION IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE EPO NOTIFIED THE COMPANY OF ITS INTENTION TO GRANT A PATENT APPLICATION COVERING THE LIQUID FORMULATION OF MOLBREEVI, AN ORALLY INHALED RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF). THE LIQUID FORMULATION AND DRUG-DEVICE PATENTS WILL PROVIDE PROTECTION IN EUROPE THROUGH MARCH 2041 AND MARCH.

SAVARA ANNOUNCES EUROPEAN PATENT OFFICE (EPO) INTENDS TO GRANT A PATENT FOR THE LIQUID FORMULATION OF MOLBREEVI*

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, ANNOUNCED THE EUROPEAN PATENT OFFICE (EPO) HAS ISSUED PATENT NO. 4 496 611 TITLED, DRUG-DEVICE COMBINATION COMPRISING A LIQUID SOLUTION AND A NEBULIZER FOR AEROSOLIZATION OF THE LIQUID SOLUTION. THE PATENT IS JOINTLY HELD BY SAVARA AND PARI AND COVERS THE COMBINATION OF SAVARA'S INVESTIGATIONAL THERAPY, MOLBREEVI, AND PARI'S INVESTIGATIONA.

SAVARA AND PARI GRANTED A EUROPEAN PATENT COVERING THE DRUG-DEVICE COMBINATION OF MOLBREEVI* DELIVERED VIA THE PROPRIETARY EFLOW NEBULIZER SYSTEM

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED MEMBERS OF THE MANAGEMENT TEAM WILL HOST ONE ON ONE MEETINGS AND PARTICIPATE IN FIRESIDE CHATS AT TWO UPCOMING HEALTHCARE CONFERENCES. FIRESIDE CHATS: PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE DECEMBER 2, 2025, 2:30PM ET EVERCORE ISI 8TH ANNUAL HEALTHCARE CONFERENCE DECEMBER 4, 2025, 10:00AM ET THE LIVE WEBCASTS AND S.

SAVARA ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR HEALTHCARE CONFERENCES

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDING SEPTEMBER 30, 2025. OUR RECENT STRATEGIC FINANCINGS FURTHER STRENGTHEN OUR BALANCE SHEET, SIGNIFICANTLY INCREASE OUR CASH RUNWAY, AND ALLOW US TO ACCELERATE OUR INVESTMENT IN PREPARING FOR THE POTENTIAL COMMERCIALIZATION OF MOLBREEVI, SAID MATT PAULS, J.D., M.B.A., CHAIR AND CHIEF EXE.

SAVARA REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN SAVARA BETWEEN MARCH 7, 2024 AND MAY 23, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , NOV. 7, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SAVARA INC. ("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA) AND REMINDS INVESTORS OF THE NOVEMBER 7, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

FINAL DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

LOS ANGELES , NOV. 7, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - SVRA

ON MAY 27, 2025, SAVARA REVEALED THE FDA REFUSED TO FILE ITS MOLBREEVI BLA DUE TO INSUFFICIENT CMC DATA, CAUSING SHARES TO FALL $0.90, OR 31.69%, TO $1.94.

SAVARA DEADLINE ALERT: BRAGAR EAGEL & SQUIRE, P.C. URGENTLY REMINDS SAVARA STOCKHOLDERS TO CONTACT THE FIRM BEFORE NOVEMBER 7TH

NEW YORK , NOV. 6, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF SAVARA INC. (NASDAQ: SVRA). SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

SHAREHOLDERS OF SAVARA INC. SHOULD CONTACT THE GROSS LAW FIRM BEFORE NOVEMBER 7, 2025 TO DISCUSS YOUR RIGHTS - SVRA

LOS ANGELES, NOV. 04, 2025 (GLOBE NEWSWIRE) -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. (SAVARA OR THE COMPANY) (NASDAQ: SVRA) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  SVRA

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED MEMBERS OF THE MANAGEMENT TEAM WILL HOST 1X1 MEETINGS AND PARTICIPATE IN FIRESIDE CHATS AT TWO UPCOMING HEALTHCARE CONFERENCES. FIRESIDE CHATS: GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE NOVEMBER 10, 2025, 8:30 A.M. ET JEFFERIES LONDON HEALTHCARE CONFERENCE NOVEMBER 19, 2025, 12:00 P.M. GMT THE LIVE WEBCASTS AND.

LOS ANGELES , NOV. 3, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SAVARA INC. ("SAVARA " OR "THE COMPANY") (NASDAQ: SVRA ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SVRA DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 28,452,381 SHARES OF COMMON STOCK, INCLUDING 4,642,857 SHARES OF COMMON STOCK SOLD PURSUANT TO THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES, AT $4.20 PER SHARE. IN ADDITION, IN LIEU OF SHARES OF COMMON STOCK, SAVARA SOLD TO CER.

SAVARA ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES FOR TOTAL GROSS PROCEEDS OF $149.5M

NEW YORK, OCT. 31, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS INSAVARA INC. ("SAVARA INC." OR THE "COMPANY") (NASDAQ: SVRA) OF A CLASS ACTION SECURITIES LAWSUIT.

INVESTORS IN SAVARA INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE NOVEMBER 7, 2025 TO DISCUSS YOUR RIGHTS  SVRA

NEW YORK, OCT. 30, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFSAVARA INC. (NASDAQ: SVRA).

SAVARA INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM FOR MORE INFORMATION  SVRA

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS INVESTORS THAT A SHAREHOLDER FILED A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF SECURITIES OF SAVARA INC. (NASDAQ: SVRA), BETWEEN MARCH 7, 2024 AND MAY 23, 2025, BOTH DATES INCLUSIVE (THE CLASS PERIOD). SAVARA IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALLEGATIONS: ROSEN LAW FIRM IS INVESTIGATING.

SVRA DEADLINE: ROSEN LAW FIRM URGES SAVARA INC. (NASDAQ: SVRA) STOCKHOLDERS TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SAVARA TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 23,809,524 SHARES OF ITS COMMON STOCK AT A PRICE OF $4.20 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE 7,142,857 SHARES OF COMMON STOCK AT A PRICE OF $4.199 PER PRE-FUNDED WARRANT, IN EACH CASE, BEFORE DEDUCTING UNDERWRITING DIS.

SAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE PROPOSED OF.

SAVARA ANNOUNCES PROPOSED PUBLIC OFFERING

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, ANNOUNCED A $75 MILLION ROYALTY FUNDING AGREEMENT WITH FUNDS MANAGED BY RTW INVESTMENTS, LP (RTW), SUBJECT TO FDA APPROVAL OF MOLBREEVI. THIS NON-DILUTIVE STRATEGIC FINANCING WILL SUPPORT THE U.S. LAUNCH OF MOLBREEVI, ASSUMING FDA APPROVAL, AND ALLOW US TO FURTHER INVEST IN COMMERCIAL PRIORITIES, SAID MATT PAULS, J.D., M.B.A., CHAIR AND CH.

SAVARA ANNOUNCES $75M ROYALTY FUNDING AGREEMENT WITH RTW TO SUPPORT THE POTENTIAL LAUNCH OF MOLBREEVI* IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

Savara Inc.

SVRA

Price

Financial Reports

No items found.

Press Releases

Savara Inc.

SVRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SVRA